JP4685374B2 - Topical skin preparation - Google Patents

Description

  The present invention relates to an external preparation for skin which synergistically improves the effect of preventing and improving rough skin and aging of the skin. More specifically, the present invention relates to an external preparation for skin comprising a combination of a β-endorphin production promoter and an anti-inflammatory agent.

  It is known that inflammatory reaction of the skin and aging of the skin progress due to aging, exposure to ultraviolet rays, oxidative stress due to reactive oxygen species generated in the skin tissue, contact with drugs and various allergens, and the like. In the field of topical skin preparations, many physiologically active ingredients such as reactive oxygen species scavengers, anti-inflammatory agents, and antiallergic agents have been searched and examined in order to prevent inflammation and aging of the skin. In addition, as it becomes clear that aging symptoms of skin progress due to cross-linking of collagen, which is a dermal matrix component, due to aging and the stress, substances having an action of promoting production in the skin tissue have been studied. ing. In recent years, there has been an increasing tendency to demand such components from plants, reflecting the natural and plant orientation of consumers.

  However, among the above-mentioned ingredients of plant origin that have already been reported, the activity is low, so that a considerably high concentration is required to obtain a sufficient effect when blended into a skin external preparation, and stability and safety are also required. When there are problems with sexuality, or there are things that give unfavorable color or odor to the external preparation for skin, when blended with external preparation for skin, all of the stability and safety of the preparation, and the action effect There are few things that can be satisfied in terms of the situation. In addition, since the inflammatory reaction and aging of the skin proceed with various factors involved in a complicated manner, sufficient effects cannot be obtained even if a substance that acts only on a part of the reaction is used.

  On the other hand, β-endorphin is contained in the brain, heart and other organs, and preproopiomelanocortin (POMC), which is a precursor protein in common with pituitary adrenocorticotropic hormone (ACTH) and melanocyte stimulating hormone (MSH). It is a kind of endogenous morphine-like peptide (opiotide peptide) biosynthesized from lysine, and is known as a brain pleasure substance because it has analgesic action and anti-stress action. It exists in the right brain and the limbic system, which are related to emotions, and plays an important role when feeling joy.

  Certain aromatic components have an effect of promoting the release of β-endorphin and can be used in aroma-related products because sniffing relaxes the body and mind and relieves stress.

  β-endorphin is particularly abundant in the middle and posterior lobe of the pituitary gland and is known to be secreted into the blood by noxious factors such as stress. However, recent research has synthesized POMC in the skin. It has been clarified that β-endorphin is liberated from epidermal keratinocytes (see Non-Patent Documents 1 and 2).

  However, the physiological action of β-endorphin on the skin is still unclear and has not been studied in detail. There is no example in which β-endorphin and / or a substance having an action of promoting the production of β-endorphin has been used in an external preparation for skin, particularly cosmetics. Therefore, the present inventors have made various studies under the hypothesis that β-endorphin secreted by stress may exert some advantageous action on the skin.

  Anti-inflammatory agents have long been incorporated into topical skin preparations in anticipation of an effect of improving rough skin. However, the combined use of β-endorphin production promoter and one or more selected from anti-inflammatory agents, and further combined use to suppress complex skin inflammatory reactions, etc. In the above-mentioned literature and the like, there has been no description or suggestion about the remarkable effect of the present invention that a skin external preparation capable of synergistically improving and preventing skin aging can be obtained.

Zenello S.B., Jackson D.M., Holick M.F. et.al., An immunocytochemical approach to the study of beta-endorphin production in human keratinocytes using confocal microscopy, Annals New York Academy of Sciences, 1999, 885 (20), 85-99 Wintzen M., Zanello S.B., Holick M.F., Wiegant V.M., Burbach J.P., Vermeer B.J., Condition-dependent presence of beta-lipotropin-like peptide in human keratinocytes, Peptides, 2000,21 (5), 691-697

  Accordingly, an object of the present invention is to obtain an external preparation for skin that suppresses complex skin inflammatory reactions and the like, and synergistically improves the effect of preventing and improving rough skin and aging of the skin.

  As a result of various studies to solve the above-mentioned problems, the present inventors have included a β-endorphin production promoter and one or more anti-inflammatory agents in combination in a skin external preparation, whereby rough skin and It has been found that synergistic improvement of skin aging prevention and improvement effects can be obtained, and the present invention has been completed.

  According to the present invention, it is possible to obtain an external preparation for skin having excellent stability and safety, and synergistically improving the effect of preventing and improving rough skin and skin aging.

  In the present invention, the β-endorphin production promoter is not particularly limited. However, it is possible to use one or more selected from the terminaria extract, eucalyptus extract, giant kelp extract, and rose water. From the point of the effect at the time of mix | blending in and the point of skin irritation, it is preferable.

Terminaria ( Terminalia sericea ) is a species of the genus Motamamana, which uses the extract. Hypericum perforatum is a species of the genus Hypericum perforatum , and its extract is used. Calendula officinalis is a species of the genus Calendula belonging to the family Asteraceae and uses its extract. Giant kelp, macro cis-Sevilla-Pirifera belonging to Lessonia family (Macrocystis pyrifera), macro-cis Sevilla integrase Li Folia (Macrocystis integrifolia), Neoshitisu-Ruetokeana (Nereocystis leutkeana) is a brown algae, such as, using the extract.

  In order to obtain these extracts, it is possible to use any part such as plants, whole plants of algae, whole algae, flowers, stems, bark, roots, buds, seeds, leaves, etc. In terms of Terminaria, it is desirable to use bark or roots. For Hypericum perforatum, it is desirable to use whole grass. For Ginseng, it is desirable to use head flowers. For giant kelp, It is desirable to use whole algae. In the extraction, it may be used as it is, but considering the extraction efficiency, it is preferable to perform the extraction after performing processing such as shredding, drying, and pulverization. The extraction can be performed by immersing in an extraction solvent or by an extraction method using a supercritical fluid or a subcritical fluid. In order to increase the extraction efficiency, stirring or homogenization may be performed in the extraction solvent. The extraction temperature is suitably about 5 ° C. to the boiling point of the extraction solvent. The extraction time varies depending on the type of extraction solvent and the extraction temperature, but it is appropriate to set it to about 1 hour to 14 days.

  Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol, and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerin, and ethers such as ethyl ether and propyl ether. , Solvents such as esters such as butyl acetate and ethyl acetate, and ketones such as acetone and ethyl methyl ketone can be used, and one or more of these are selected and used. Further, physiological saline, phosphate buffer, phosphate buffered saline, or the like may be used. Furthermore, you may use 1 type, or 2 or more types of supercritical fluids and subcritical fluids, such as water, a carbon dioxide, ethylene, propylene, ethanol, methanol, ammonia.

  In addition, the extract can be added to the external preparation base as it is, but the concentrated and dried solid can be dissolved again in water or a polar solvent, or purified or fractionated by decolorization, deodorization, desalting, etc. You may use it after. For storage, it is preferable to freeze-dry after the purification treatment and dissolve in a solvent before use. Alternatively, they can be encapsulated in vesicles such as liposomes, microcapsules and the like.

Moreover, the rose water uses the aqueous component which has the fragrance obtained by steam-distilling the flower of damasks rose ( Rosa damascena Miller) or centifolia rose ( Rosa centifolia L.).

  In the present invention, the blending amount of the β-endorphin production promoter in the external preparation for skin is preferably 0.00001 to 10% by weight, more preferably 0.0001 to 5% by weight. In the present application, when used in combination with an anti-inflammatory agent, an effective effect of preventing rough skin and preventing skin aging and improving can be obtained in a much smaller amount than when a β-endorphin production promoter is used alone.

  In the present invention, the anti-inflammatory agent used in combination with the β-endorphin production promoter is cortisone, hydrocortisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide, beclomethasone and these Steroidal anti-inflammatory agents such as phosphate, propionate, acetate, succinate, salicylic acid and salicylic acid derivatives such as aspirin, salicylamide, etenzamide, methyl salicylate, indoleacetic acid derivatives such as indomethacin, sulindac, phenylbuta Pyrazolidinedione derivatives such as zon and oxyphenbutazone, anthranilic acid derivatives such as mefenamic acid and flufenamic acid, ibuprofen, ketoprofen, naprox Non-steroidal anti-inflammatory agents such as propionic acid derivatives such as diclofenac, fenbufen and bufexamac, benzothiazine derivatives such as piroxicam, derivatives of glycyrrhizic acid such as dipotassium glycyrrhizinate and dipotassium glycyrrhizinate and monoammonium glycyrrhizinate, and the like Glycyrrhetinic acid and stearyl glycyrrhetinate, glycyrrhetinic acid stearyl, glycyrrhetinic acid stearate, 3-succinyloxyglycyrrhetinic acid disodium derivative and their salts, guaiazulene, guaiazulene sulfonic acid ethyl, guaiazulene sulfonic acid sodium, camazulene Allantoin, aloin, aloe emodin, shikonin and isobutyl shikonin, acetyl shikonin, Shikonin derivatives such isovalerate Lil shikonin, Ginsenoside Ra1, Ginsenoside Ra2, Ginsenoside such Ginsenoside Rb1, and 20-ginsenoside derivatives such as glucosides Gin Seno glucoside Rf, paeoniflorin, paeonol and Peonoshido, like paeonol derivatives such Peonorido.

As anti-inflammatory agent in the present invention, scutellaria root (Scutellariae Radix), Coptis (Coptidis Rhizoma), licorice (Glycyrrhizae Radix), Sophora root (Sophorae Radix), Psycho (Bupleuri Radix), peony (Paeoniae Radix), Cimicifuga (Cimicifugae Rhizoma ), Tizou ( Zizyphi Fructus ), Chimo ( Anemarrhenae Rhizoma ), Buttonpi ( Moutan Cortex ), Ryutan ( Gentianae Scabrae Radix ), Forsythiae Fructus , Shikon ( Lithospermi Radix ), Carrot ( Ginseng Radix, etc.) The crude drug used or its extract can also be used.

  For the external preparation for skin according to the present invention, one or more of these anti-inflammatory agents are selected and used.

  The anti-inflammatory agent in the present invention is selected from glycyrrhizic acid and derivatives thereof and salts thereof, glycyrrhetinic acid and derivatives thereof and salts and aurene because of its ease of incorporation into an external preparation for skin. Or 2 or more types are preferably used, and it is preferable to use 1 type, or 2 or more types selected from dipotassium glycyrrhizinate, stearyl glycyrrhetinate, and auren from the point of the rough skin improvement effect.

  In this invention, (beta) -endorphin production promoter and the 1 type (s) or 2 or more types of an anti-inflammatory agent are contained in a skin external preparation base. The blending amount per total amount of the external preparation for skin is appropriately about 0.0001 to 5.0% by weight, although it varies depending on the type of anti-inflammatory agent.

  The external preparation for skin according to the present invention can be provided in various dosage forms such as lotions, emulsions, gels, creams, ointments, powders, granules and the like. In addition, skin cosmetics such as lotion, milky lotion, cream, beauty essence, packs, foundation cosmetics such as makeup base lotion and makeup base cream, foundations for each dosage form such as emulsion, oily, solid, etc. It can be provided as makeup cosmetics such as color and teak color, and body cosmetics such as hand cream, leg cream, neck cream and body lotion.

  In addition to the β-endorphin production promoter and the anti-inflammatory agent, the external preparation for skin according to the present invention includes oil components, surfactants, moisturizers, pigments, ultraviolet absorbers, antioxidants, perfumes, antibacterial and antimicrobial agents. General pharmaceutical ingredients such as glazes and raw materials for cosmetics, and physiologically active ingredients such as skin cell activators and whitening agents can be included.

  Further, the features of the present invention will be described in detail by way of examples. In addition, unless otherwise indicated, the quantity in an Example was shown by weight%.

  First, each extract used in the present invention was prepared as follows.

[Production Example 1] Terminaria extract 1 kg of a mixture of dried bark and dried root of Terminaria was pulverized, added to 9 L of methanol, and immersed for 7 days at room temperature with stirring. The extract was collected by filtration and the solvent was removed to obtain a dried extract. The obtained extract dried product was dissolved in a mixture of 1,3-butylene glycol: water = 1: 1 so as to be 0.8% by weight to obtain a terminaria extract.

[Production Example 2] Hypericum perforatum extract 1 kg of dried whole plant of Hypericum perforatum was pulverized, added to 9 L of 50 wt% 1,3-butylene glycol aqueous solution, and immersed for 7 days at room temperature with stirring. The extract was collected by filtration and the solvent was removed to obtain a dried extract. The obtained extract and dried product was dissolved in a mixture of 1,3-butylene glycol: water = 1: 1 so as to be 2.0% by weight to obtain a Hypericum perforatum extract.

[Manufacturing Example 3] Milky Scenter Extract 1 kg of dried flower of eucalyptus was pulverized, added to 9 L of 50% by weight ethanol aqueous solution, and immersed for 7 days at room temperature with stirring. The extract was collected by filtration and the solvent was removed to obtain a dried extract. The obtained extract and dried product was dissolved in a mixture of 1,3-butylene glycol: water = 1: 1 so as to be 2.0% by weight to obtain a milk extract.

[Production Example 4] Giant kelp extract 1 kg of a dried whole alga of giant kelp ( Macrocustis pyrifera ) was pulverized, added to 9 L of a 3 wt% aqueous sodium chloride solution, and homogenized at room temperature. The extract was collected by filtration, and the solvent was removed to obtain a giant kelp extract as an extract dried product.

[Production Example 5] 1 kg of a flower collected just before flowering of rose water centifolia rose ( Rosa centifolia L.) was separated into a fragrance component and a water-soluble component by a steam distillation method. Rose water was obtained by filtering the water-soluble component.

  Moreover, what was marketed as a pharmaceutical or cosmetics was used for the anti-inflammatory agent mix | blended in the following Example of this invention. The preparation of the anti-inflammatory crude drug extract is described below.

[Production Example 6] Licorice extract 500 g of licorice ( Glycyrrhizae Radix ) was dried, ground, and extracted in 1 liter of hot water for 2 hours. The filtrate was collected by filtration, then concentrated under reduced pressure and then lyophilized to obtain the title extract.

[Production Example 7] Ouren extract 500 g of Ouren ( Coptidis Rhizoma ) was dried, pulverized, immersed in 1 liter of 50 vol% ethanol aqueous solution, and extracted at 25 ° C. for 7 days. The filtrate was collected by filtration and used as the title extract.

[Production Example 8] Kujin extract 500 g of Kujin ( Sophorae Radix ) was dried, pulverized, immersed in 1 liter of 50 vol% ethanol aqueous solution and extracted at 25 ° C. for 7 days. The filtrate was collected by filtration and used as the title extract.

[Production Example 9] Peonies extract 550 g of peonies ( Paeoniae Radix ) was dried, pulverized, immersed in 1 liter of 50 vol% ethanol aqueous solution, and extracted at 20 ° C. for 10 days with stirring. The filtrate was then collected by filtration, concentrated under reduced pressure, and lyophilized to give the title extract.

[Production Example 10] Button pi extract 520 g of button pi ( Moutan Cortex ) was dried, pulverized, immersed in 1 liter of ethanol, allowed to stand at 10 ° C. for 14 days, and extracted. The filtrate was collected by filtration and used as the title extract.

[Production Example 11] Ryutan extract 650 g of Ryutan ( Gentianae Scabrae Radix ) was dried, ground and extracted in 1 liter of hot water for 4 hours. The filtrate was collected by filtration, concentrated under reduced pressure, and lyophilized to give the title extract.

[Production Example 12] Forsythiae Fructus Forsythiae Fructus 750 g was pulverized, immersed in 1.2 liters of 1,3-butylene glycol, and extracted at 15 ° C. for 10 days with stirring. The filtrate was collected by filtration and used as the title extract.

  It continues and the prescription of the Example about the skin external preparation which concerns on this invention is shown.

[Examples 1 to 10, Comparative Examples 1 to 8] Oil-in-water cream (1) Beeswax 6.00
(2) Cetanol 5.00
(3) Reduced lanolin 8.00
(4) Squalane 27.50
(5) Glyceryl fatty acid ester 4.00
(6) Lipophilic glyceryl monostearate 2.00
(7) Polyoxyethylene (20E.O.) sorbitan monolaurate 5.00
(8) Stearyl glycyrrhetinate 0.25
(9) Propylene glycol 5.00
(10) Methyl paraoxybenzoate 0.10
(11) Purified water Amount based on 100 (12) β-endorphin production promoter Amount shown in Table 1 (13) Anti-inflammatory agent Amount production method shown in Table 1: Oil phase components (1) to (8) Mix and dissolve to 75 ° C. On the other hand, the aqueous phase components (9) to (11) are mixed and dissolved, and heated to 75 ° C. Next, the oil phase component is added to the aqueous phase component and pre-emulsified, and then uniformly emulsified with a homomixer. After cooling, (12) and (13) are added and mixed at 40 ° C.

About Example 1- Example 10 shown in Table 1, and Comparative Example 1- Comparative Example 8, the inhibitory effect with respect to wrinkle formation of the skin by medium wavelength ultraviolet rays (UVB) was evaluated. The evaluation was conducted by making 5 hairless mice into one group, applying 0.2 g of each of Examples and Comparative Examples once a day to the back of each group, and applying UVB of 100 mJ / cm ² / times three times a week. Irradiated for 20 weeks, the state of wrinkle formation in the hairless mouse skin was observed, and scored according to the criteria shown in Table 2 for evaluation. As a result, the average value of each group was calculated and shown in Table 3 according to the relationship with the number of days of UVB irradiation.

  As is clear from Table 3, in Comparative Example 8 in which neither the β-endorphin production promoter nor the anti-inflammatory agent was blended, the depth of wrinkles formed on the skin when the UVB irradiation days exceeded 10 weeks. Reached moderate to moderate, and after 20 weeks, moderate wrinkle formation was observed. In Comparative Example 1 to Comparative Example 5 containing only the β-endorphin production promoter as an active ingredient and Comparative Example 6 and Comparative Example 7 containing only the anti-inflammatory agent, slight to moderate wrinkles were observed after 20 weeks. The formation of was recognized. On the other hand, in the example application group, even after 20 weeks, the formation of wrinkles was significantly suppressed as compared with the corresponding comparative examples, to the extent that formation of fine to slight wrinkles was observed.

  Subsequently, a use test was conducted on Examples 1 to 10 and Comparative Examples 1 to 8 of the present invention to evaluate the effect of improving skin aging symptoms.

  The effect of improving skin aging symptoms is that 20 female panelists in their 40's to 60's in which fine wrinkle formation and skin elasticity are markedly reduced are considered as one group, and each of the examples and comparative examples is blinded in each group. And used continuously twice a day for 2 months. The degree of fine lines is evaluated by visual observation and photography, and the skin elasticity is measured by a cut meter, and the state before and after the use test is started and compared, respectively. “Improved”, “Slightly improved”, “Change” It was evaluated in three stages, “none”. The results are shown in Table 4 for fine lines and Table 5 for skin elasticity in terms of the number of panelists obtained for each evaluation.

  As is apparent from Tables 4 and 5, in Comparative Examples 1 to 7 in which a β-endorphin production promoter or anti-inflammatory agent was blended alone, compared with Comparative Example 8 containing no active ingredient, Although the wrinkle and skin elasticity improvement effect was recognized, the degree was lower than Examples 1-10 which mix | blended combining the beta-endorphin production promoter and the anti-inflammatory agent.

  Moreover, the improvement effect of the rough skin symptom was evaluated about Example 1-Example 10 and Comparative Example 1-Comparative Example 8 of this invention. The improvement effect of rough skin symptoms is a group of 20 female panelists in their 20s to 60s who show remarkable rough skin symptoms, and each of the examples and comparative examples is blinded twice a day. Evaluated by using continuously for months. The skin condition before and after the start of the use test was evaluated and scored according to the evaluation criteria shown in Table 6, and the average value of 20 people was calculated and shown in Table 7.

  As is clear from Table 7, in the examples using group of the present invention, remarkable improvement in rough skin was observed in any of the examples, and after completion of the use test, the skin condition was improved from almost good to good. . On the other hand, although the improvement of the rough skin was recognized also in the comparative example use group, the degree was small compared with the corresponding Example use group.

[Example 11] Lotion agent (1) Ethanol 20.0
(2) Polyoxyethylene (60E.O.) hydrogenated castor oil 1.0
(3) Terminaria extract 0.2
(4) Dipropylene glycol 5.0
(5) 1,3-butylene glycol 10.0
(6) Sodium guaiazulene sulfonate 0.2
(7) Methyl paraoxybenzoate 0.1
(8) Purified water Mass production method with a total amount of 100: Components (1) to (7) are added sequentially to (8) to dissolve and homogenize.

[Example 12] Emulsion (1) Cetanol 1.0
(2) Beeswax 0.5
(3) Vaseline 2.0
(4) Squalane 6.0
(5) Dimethylpolysiloxane 2.0
(6) Polyoxyethylene (20E.O.) sorbitan monostearate ester 1.0
(7) Glyceryl monostearate ester 1.0
(8) Glycerin 4.0
(9) 1,3-butylene glycol 4.0
(10) Methyl paraoxybenzoate 0.1
(11) Purified water Amount based on the total amount of 100 (12) Carboxyvinyl polymer (1.0% aqueous solution) 10.0
(13) Potassium hydroxide (10.0% aqueous solution) 1.0
(14) Hypericum perforatum extract 0.1
(15) Allantoin 0.2
(16) Ethanol 5.0
Production method: The oil phase components (1) to (7) are mixed and dissolved by heating to 75 ° C. On the other hand, the water phase components (8) to (11) are mixed and dissolved to 75 ° C. After preliminarily emulsifying by adding the oil phase to this, (12) was added and uniformly emulsified with a homomixer, and then (13) was added to increase the viscosity, followed by cooling at 40 ° C. (14) Add ~ 16 and mix.

Example 13 Emulsion (1) Cetanol 1.0
(2) Beeswax 0.5
(3) Vaseline 2.0
(4) Squalane 6.0
(5) Dimethylpolysiloxane 2.0
(6) Polyoxyethylene (20E.O.) sorbitan monostearate ester 1.0
(7) Glyceryl monostearate ester 1.0
(8) Stearyl glycyrrhetinate 0.2
(9) Glycerin 4.0
(10) 1,3-butylene glycol 4.0
(11) Methyl paraoxybenzoate 0.1
(12) Purified water Amount based on 100 (13) Carboxyvinyl polymer (1.0% aqueous solution) 10.0
(14) Potassium hydroxide (10.0% aqueous solution) 1.0
(15) Ethanol 5.0
(16) Licorice extract 0.2
(17) Tokashinka extract 0.1
Production method: The oil phase components (1) to (8) are mixed and dissolved by heating to 75 ° C. On the other hand, the aqueous phase components (9) to (12) are mixed and dissolved to 75 ° C. After preliminarily emulsifying by adding the oil phase to this, (13) is added and uniformly emulsified with a homomixer, and then (14) is added to increase the viscosity, followed by cooling at 40 ° C. (15) Add ~ (17) and mix.

[Example 14] Oil-in-water cream (1) Beeswax 6.0
(2) Cetanol 5.0
(3) Reduced lanolin 8.0
(4) Squalane 27.5
(5) Glyceryl fatty acid ester 4.0
(6) Lipophilic glyceryl monostearate 2.0
(7) Polyoxyethylene (20E.O.) sorbitan monolaurate 5.0
(8) Propylene glycol 5.0
(9) Methyl paraoxybenzoate 0.1
(10) Purified water Amount based on 100 (11) Giant kelp extract 0.05
(12) Kujin extract 0.1
Production method: The oil phase components (1) to (7) are mixed and dissolved to 75 ° C. On the other hand, the water phase components (8) to (10) are mixed and dissolved, and heated to 75 ° C. Next, the oil phase component is added to the aqueous phase component and pre-emulsified, and then uniformly emulsified with a homomixer. After cooling, (11) and (12) are added and mixed at 40 ° C.

Example 15 Gel Agent (1) Dipropylene glycol 10.0
(2) Carboxyvinyl polymer 0.5
(3) Methyl paraoxybenzoate 0.1
(4) Rosewater 2.0
(5) Peonies extract 0.3
(6) Potassium hydroxide (10.0% aqueous solution) 1.0
(7) Purified water A mass production method with a total amount of 100: (1) to (5) are uniformly dissolved in (7), and then (6) is added to increase the viscosity.

Example 16 Oil-in-water emulsion type ointment (1) White petrolatum 25.0
(2) Stearyl alcohol 25.0
(3) Glycerin 12.0
(4) Sodium lauryl sulfate 1.0
(5) Methyl paraoxybenzoate 0.1
(6) Purified water Amount based on 100 (7) Hypericum perforatum extract 0.1
(8) Button pi extract 1.0
Production method: The oil phase components (1) to (4) are mixed and heated to dissolve uniformly to 75 ° C. On the other hand, the aqueous phase components (5) to (6) are mixed and heated to 75 ° C. The oil phase component is gradually added to the aqueous phase component while stirring to emulsify, and after cooling, (7) and (8) are added and mixed at 40 ° C.

[Example 17] Liposome agent (1) Glycerin 2.0
(2) 1,3-butylene glycol 3.0
(3) Polyoxyethylene (25E.O.) oleyl ether 0.2
(4) Ethanol 10.0
(5) Methyl paraoxybenzoate 0.1
(6) Purified water Amount that makes the total amount 100 (7) Terminaria extract, Ouren extract encapsulated liposome
5.0
Production method: Dissolve (5) in (4), add to (6) together with (1) to (3), mix uniformly, add (7) to this and disperse. In addition, the terminaria extract and the auren extract-encapsulating liposome of (7) is a 50 vol% ethanol aqueous solution containing 1.0 (w / v)% of the terminaria extract and 2.0 (w / v) of the auren extract. To 100 mL, 80 g of soybean lecithin was added and suspended at 55 ° C., and then sonicated to prepare liposomes, which were collected by centrifugation.

[Example 18] Water-in-oil emollient cream (1) Liquid paraffin 30.0
(2) Microcrystalline wax 2.0
(3) Vaseline 5.0
(4) Diglyceryl dioleate 5.0
(5) Sodium L-glutamate 1.6
(6) L-serine 0.4
(7) Propylene glycol 3.0
(8) Methyl paraoxybenzoate 0.1
(9) Tokakinka extract 0.1
(10) Forsythia extract 1.5
(11) Purified water Amount based on 100 (12) Fragrance 0.1
Production method: Dissolve (5) and (6) in a part of (11) to 50 ° C., and gradually add to (4) heated in advance to 50 ° C. with stirring. This is mixed in advance and uniformly dispersed in (1) to (3) heated and dissolved at 70 ° C. (7) to (10) are added to the remainder of (11), and the mixture heated to 70 ° C. is added with stirring and emulsified with a homomixer. After cooling, add and mix (12) at 40 ° C.

[Example 19] Make-up base cream (1) Stearic acid 12.00
(2) Cetanol 2.00
(3) Glyceryl tri-2-ethylhexanoate 2.50
(4) Self-emulsifying glyceryl monostearate 2.00
(5) Propylene glycol 10.00
(6) Giant Kelp Ellis 0.02
(7) Methyl paraoxybenzoate 0.10
(8) Ryutan extract 0.05
(9) Potassium hydroxide 0.30
(10) Purified water Amount based on 100 (11) Titanium oxide 2.00
(12) Bengala 0.40
(13) Yellow iron oxide 0.10
(14) Fragrance 0.10
Production method: The oil phase components (1) to (4) are mixed and dissolved to 75 ° C. On the other hand, the aqueous phase components (5) to (10) are mixed, dissolved by heating, and the pigment components (11) to (13) are added thereto and dispersed uniformly with a homomixer to 75 ° C. Next, the oil phase component is added to the water phase component, and the mixture is uniformly emulsified with a homomixer. After cooling, (14) is added and mixed at 40 ° C.

[Example 20] Emulsion foundation (1) Stearic acid 2.00
(2) Squalane 5.00
(3) Octyl dodecyl myristate 5.00
(4) Cetanol 1.00
(5) Decaglyceryl monoisopalmitate 9.00
(6) 1,3-Butylenecricol 6.00
(7) Methyl paraoxybenzoate 0.10
(8) Potassium hydroxide 0.08
(9) Purified water Amount that makes the total amount 100 (10) Titanium oxide 9.00
(11) Talc 7.40
(12) Bengala 0.50
(13) Yellow iron oxide 1.10.
(14) Black iron oxide 0.10
(15) Rose water 1.00
(16) Button pi extract 1.00
(17) Fragrance 0.15
Production method: The oil phase components (1) to (5) are mixed and dissolved to 75 ° C. On the other hand, the aqueous phase components (6) to (9) are mixed, dissolved by heating, the pigment components (10) to (14) are added thereto, and the mixture is uniformly dispersed with a homomixer to 75 ° C. Next, the oil phase component is added to the aqueous phase component, and the mixture is uniformly emulsified with a homomixer. After cooling, (15) to (17) are added and mixed at 40 ° C.

[Example 21] Hand cream (1) Cetanol 4.00
(2) Vaseline 2.00
(3) Liquid paraffin 10.00
(4) Glyceryl monostearate 1.50
(5) Polyoxyethylene (60E.O.) glyceryl 2.50
Isostearic acid ester (6) Tocopherol acetate 0.25
(7) Glycerin 20.00
(8) Methyl paraoxybenzoate 0.10
(9) Terminaria extract 0.05
(10) Dipotassium glycyrrhizinate 0.02
(11) Purified water Mass production method with a total amount of 100: The oil phase components (1) to (6) are mixed and dissolved to 75 ° C. On the other hand, the aqueous phase components (7) to (11) are mixed and dissolved to 75 ° C. Next, the oil phase component is added to the aqueous phase component, and the mixture is uniformly emulsified with a homomixer and cooled.

[Example 22] Pack (1) Purified water Amount based on the total amount of 100 (2) Polyvinyl alcohol 12.5
(3) Ethanol 10.0
(4) Glycerin 5.0
(5) Polyethylene glycol (average molecular weight 1540) 3.0
(6) Hypericum perforatum extract 0.2
(7) Licorice extract 0.2
Production method: Components (2) to (7) are sequentially added to (1) to mix, dissolve and homogenize.

[Example 23] Hair tonic (1) Ethanol 50.0
(2) Purified water Amount based on 100 (3) Dipotassium glycyrrhizinate 0.1
(4) Milky Scent extract 0.5
Production method: Components (1) to (4) are mixed and dissolved uniformly.

[Example 24] Hair shampoo (1) Sodium alkyl ether sulfate 18.0
(2) Palm oil fatty acid diethanolamide 2.0
(3) Propylene glycol 2.0
(4) Giant kelp extract 0.03
(5) Allantoin 0.1
(6) Purified water Mass production method with a total amount of 100: Components (1) to (5) are sequentially added to (6) to make uniform.

[Example 25] Hair rinse (1) Cetanol 3.0
(2) Stearyltrimethylammonium chloride 0.7
(3) Glycerin 3.0
(4) N-cocoyl-L-arginine ethyl ester
-DL-pyrrolidonecarboxylate 0.1
(5) Allantoin 0.1
(6) Rose water 0.7
(7) Purified water Mass production method with a total amount of 100: The components (1) to (6) are added to (7) sequentially and mixed.

[Example 26] Liquid body shampoo (1) N-lauroyl-L-glutamic acid
Triethanolamine (30.0% aqueous solution) 20.0
(2) N-lauroylmethyl taurine sodium
(30.0% aqueous solution) 10.0
(3) lauric acid triethanolamine 10.0
(4) Triethanolamine myristic acid 10.0
(5) Lauroi imidazolinium betaine 5.0
(6) Lauroyl diethanolamide 5.0
(7) Propylene glycol 7.0
(8) Terminaria extract 0.3
(9) Licorice extract 0.5
(10) Purified water Mass production method with a total amount of 100: Components (1) to (9) are added to (10) sequentially and mixed.

[Example 27] Face-wash foam (1) Myristic acid 18.0
(2) Palmitic acid 3.0
(3) Stearic acid 7.0
(4) Mixed fatty acid triglyceride 0.1
(5) Stearyl glycyrrhetinate 0.1
(6) Self-emulsifying glyceryl monostearate 3.0
(7) Purified water Amount based on 100 (8) Glycerin 17.0
(9) Potassium hydroxide 7.8
(10) Diglycerin 3.0
(11) 1,3-butylene glycol 1.0
(12) Disodium N-stearolyl-L-glutamate 1.0
(13) Methyl paraoxybenzoate 0.1
(14) Tokakinka extract 0.3
(15) Stearyl glycyrrhetinate 0.1
(16) Licorice extract 0.5
Production method: The oil phase components (1) to (6) are mixed, heated and dissolved to 70 ° C. The aqueous phase components (7) to (16) are mixed, dissolved, and heated to 70 ° C. The oil phase is gradually added to the aqueous phase component to saponify it, and then cooled while mixing.

  In Examples 1 to 27, no change in state was observed when stored at 25 ° C. for 6 months, and the skin irritation was problematic even in the 48-hour back obstruction test with 30 male panelists. Sexual reaction was not observed.

Claims (1)

(A) β-endorphin production promoter comprising Terminaria extract as an active ingredient, and (B) glycyrrhizic acid and derivatives thereof and salts thereof, glycyrrhetinic acid and derivatives thereof and salts thereof , licorice extract A skin external preparation for improving rough skin and anti-aging, comprising one or more anti-inflammatory agents .